{"protocolSection": {"identificationModule": {"nctId": "NCT00806442", "orgStudyIdInfo": {"id": "2008p001696"}, "secondaryIdInfos": [{"id": "P50AT002782", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/P50AT002782"}], "organization": {"fullName": "Brigham and Women's Hospital", "class": "OTHER"}, "briefTitle": "Treatment of Bronchial Asthma With Borage and Echium Seed Oils", "officialTitle": "Treatment of Bronchial Asthma With Borage and Echium Seed Oils"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-12"}, "primaryCompletionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-12-09", "studyFirstSubmitQcDate": "2008-12-09", "studyFirstPostDateStruct": {"date": "2008-12-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-07-16", "resultsFirstSubmitQcDate": "2017-06-06", "resultsFirstPostDateStruct": {"date": "2017-07-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-06-06", "lastUpdatePostDateStruct": {"date": "2017-07-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Elliot Israel, MD", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Brigham and Women's Hospital"}, "leadSponsor": {"name": "Brigham and Women's Hospital", "class": "OTHER"}, "collaborators": [{"name": "Wake Forest University Health Sciences", "class": "OTHER"}, {"name": "National Center for Complementary and Integrative Health (NCCIH)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The aim of this trial is to determine the efficacy of a combination of two botanicals oils, borage seed oil and echium seed oil, as a potential treatment for bronchial asthma.", "detailedDescription": "Leukotrienes are important in the pathogenesis of inflammation, and leukotriene modifying drugs are now an established treatment for bronchial asthma and rhinitis. Drugs that inhibit the biosynthesis of leukotrienes are likely to be more effective than the currently available drugs that antagonize a single leukotriene receptor. Dietary supplementation with gamma linolenic acid (GLA) in borage seed oil provides effective inhibition of leukotriene generation but also increases circulating free arachidonic acid (AA), which has pro-inflammatory potential. The n-3 fatty acid, eicosapentaenoic acid (EPA), prevented the conversion of GLA to AA. However, EPA is extracted from fish oil, is not well-tolerated due to its taste, and at higher doses appeared to blunt the inhibition of leukotriene biosynthesis by GLA. Stearidonic acid (SDA) is a precursor of EPA that is extracted from Echium plantagineum; it is converted to EPA in humans and it does not have the organoleptic properties of EPA.\n\nWe recently completed a dose-ranging study in which we determined the dose of SDA that is sufficient to inhibit the rise in circulating levels of arachidonic acid while maintaining effective inhibition of leukotriene generation.\n\nThe goal of the present study is to test the efficacy of dietary supplementation with GLA and SDA (provided in borage seed oil and echium seed oil) in treating bronchial asthma."}, "conditionsModule": {"conditions": ["Bronchial Asthma"], "keywords": ["Asthma", "Fatty acids", "Leukotrienes", "Diet"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 43, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1: Borage Seed Oil and Echium Seed Oil", "type": "EXPERIMENTAL", "description": "Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.", "interventionNames": ["Drug: Borage Seed Oil and Echium Seed Oil"]}, {"label": "2: Placebo Comparator", "type": "PLACEBO_COMPARATOR", "description": "Placebo comparator: 9 g/day corn oil", "interventionNames": ["Dietary Supplement: Corn Oil"]}], "interventions": [{"type": "DRUG", "name": "Borage Seed Oil and Echium Seed Oil", "description": "2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.", "armGroupLabels": ["1: Borage Seed Oil and Echium Seed Oil"], "otherNames": ["CROSSENTIAL GLA TG40", "INCROMEGA V3"]}, {"type": "DIETARY_SUPPLEMENT", "name": "Corn Oil", "description": "9 g/day of corn oil", "armGroupLabels": ["2: Placebo Comparator"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1)", "description": "Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo", "timeFrame": "6 weeks"}], "secondaryOutcomes": [{"measure": "Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes", "description": "Number of participants with positive change in FEV1 % predicted (\\>0%) among C allele carriers and A homozygotes in each arm", "timeFrame": "6 weeks on each treatment assignment"}, {"measure": "Peak Flow Rate (PEFR)", "description": "Morning Peak Flow Rate in plant seed oil vs. placebo", "timeFrame": "6 weeks"}, {"measure": "Frequency of Rescue Use of Short Acting Beta-2 Agonists", "description": "Average number of puffs of albuterol daily in plant seed oil vs. placebo", "timeFrame": "6 weeks"}, {"measure": "Day-time Symptoms of Bronchial Asthma", "description": "Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms\n\n1. = Mild: Symptom did not interfere with normal daily activity or sleep\n2. = Moderate: Symptom was sufficient to interfere with normal daily activity or sleep\n3. = Severe: Symptom was so severe as to prevent normal daily activity or sleep\n\nThese numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.\n\nThe total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.", "timeFrame": "6 weeks"}, {"measure": "Night-time Wakenings", "description": "Average number of night-time wakenings in plant seed oil vs. placebo", "timeFrame": "6 weeks"}, {"measure": "Urinary Leukotriene Levels", "description": "Urinary leukotriene levels in plant seed oil vs. placebo", "timeFrame": "6 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of bronchial asthma\n* Male or female 18 years to 65 years of age\n* FEV1 50 to 90% of predicted, or personal best.\n* Improvement of \\>=12% FEV1 with bronchodilator\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* Smoking history of \\> 10 pack years or active smoking within the past year.\n* Due to possible effects on leukotriene biosynthesis, use of the following asthma treatments within the preceding month will be exclusion criteria:\n\n  * leukotriene modifying drugs,\n  * theophylline\n  * oral steroids.\n  * dietary supplements with fatty acids or other products that may interfere with leukotriene generation.\n* Treatment within the previous three months with omalizumab (monoclonal antibody directed against IgE)\n* Subjects will not be permitted to take non-steroidal anti-inflammatory drugs in the week prior to any measurements of ex vivo leukotriene generation because of their effects on leukotriene biosynthesis via inhibition of prostaglandin generation.\n* A history of aspirin-sensitive asthma\n* Significant abnormalities in CBC, differential white cell count, renal function, and liver function, or urinalysis.\n* Any serious co-morbid medical condition.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Elliot Israel, MD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Asthma Research Center, Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}, "referencesModule": {"references": [{"pmid": "12716664", "type": "BACKGROUND", "citation": "James MJ, Ursin VM, Cleland LG. Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr. 2003 May;77(5):1140-5. doi: 10.1093/ajcn/77.5.1140."}, {"pmid": "8609415", "type": "BACKGROUND", "citation": "Chilton-Lopez, Surette ME, Swan DD, Fonteh AN, Johnson MM, Chilton FH. Metabolism of gammalinolenic acid in human neutrophils. J Immunol. 1996 Apr 15;156(8):2941-7."}, {"pmid": "9237935", "type": "BACKGROUND", "citation": "Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr. 1997 Aug;127(8):1435-44. doi: 10.1093/jn/127.8.1435."}, {"pmid": "10917903", "type": "BACKGROUND", "citation": "Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr. 2000 Aug;130(8):1925-31. doi: 10.1093/jn/130.8.1925."}, {"pmid": "12852710", "type": "BACKGROUND", "citation": "Surette ME, Koumenis IL, Edens MB, Tramposch KM, Chilton FH. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther. 2003 Mar;25(3):948-71. doi: 10.1016/s0149-2918(03)80116-9."}, {"pmid": "12852711", "type": "BACKGROUND", "citation": "Surette ME, Koumenis IL, Edens MB, Tramposch KM, Clayton B, Bowton D, Chilton FH. Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial. Clin Ther. 2003 Mar;25(3):972-9. doi: 10.1016/s0149-2918(03)80117-0."}, {"pmid": "25485197", "type": "DERIVED", "citation": "Kazani S, Arm JP, Boyce J, Chhay H, Dutile S, Wechsler ME, Govindarajulu U, Ivester P, Ainsworth HC, Sergeant S, Chilton FH, Israel E. LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma. Springerplus. 2014 Nov 6;3:661. doi: 10.1186/2193-1801-3-661. eCollection 2014."}], "seeAlsoLinks": [{"label": "Asthma Research Center, Brigham and Women's Hospital", "url": "http://asthmabwh.org"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "43 subjects were enrolled and signed consent; however, only 39 were randomized into a treatment group. 3 subjects screen failed and 1 subject was lost to follow up prior to randomization.", "groups": [{"id": "FG000", "title": "1 - Borage Seed Oil and Echium Seed Oil, Then Placebo", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA) 3x day for 3 weeks followed a 3-week washout period, then Placebo (11 g/day corn oil) 3x day for 3 weeks."}, {"id": "FG001", "title": "2 - Placebo, Then Borage Seed Oil and Echium Seed Oil", "description": "Placebo (11 g of corn oil/day) 3x day for 3 weeks followed by a 3-week washout period, then Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA) 3x day for 3 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "21"}]}, {"type": "First Intervention (3 Wks)", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "21"}]}, {"type": "Washout (3 Wks)", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Second Intervention (3 Wks)", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Study Particpants", "description": "Includes patients scheduled to receive Borage and Echium seed oil first and participants scheduled to receive placebo first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}]}], "measures": [{"title": "Age, Customized", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"title": "Age", "categories": [{"measurements": [{"groupId": "BG000", "value": "43", "lowerLimit": "22", "upperLimit": "64"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Age Category", "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "39"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Gender", "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume in 1 Second (FEV1)", "description": "Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo", "populationDescription": "Includes participants that completed the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.31", "lowerLimit": "2.22", "upperLimit": "2.39"}, {"groupId": "OG001", "value": "2.25", "lowerLimit": "2.17", "upperLimit": "2.34"}]}]}]}, {"type": "SECONDARY", "title": "Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes", "description": "Number of participants with positive change in FEV1 % predicted (\\>0%) among C allele carriers and A homozygotes in each arm", "populationDescription": "Patients who are C allele carriers or A homozygotes", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 weeks on each treatment assignment", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"title": "C-allele Carriers", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "A Homozygotes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Peak Flow Rate (PEFR)", "description": "Morning Peak Flow Rate in plant seed oil vs. placebo", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters/minute", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "337.13", "lowerLimit": "328.43", "upperLimit": "345.82"}, {"groupId": "OG001", "value": "339.34", "lowerLimit": "330.65", "upperLimit": "348.04"}]}]}]}, {"type": "SECONDARY", "title": "Frequency of Rescue Use of Short Acting Beta-2 Agonists", "description": "Average number of puffs of albuterol daily in plant seed oil vs. placebo", "populationDescription": "one participant is missing some data on this measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Avg number of puffs of albuterol daily", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.69", "lowerLimit": "0.42", "upperLimit": "0.97"}, {"groupId": "OG001", "value": "0.50", "lowerLimit": "0.23", "upperLimit": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Day-time Symptoms of Bronchial Asthma", "description": "Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms\n\n1. = Mild: Symptom did not interfere with normal daily activity or sleep\n2. = Moderate: Symptom was sufficient to interfere with normal daily activity or sleep\n3. = Severe: Symptom was so severe as to prevent normal daily activity or sleep\n\nThese numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.\n\nThe total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.51", "lowerLimit": "1.79", "upperLimit": "3.22"}, {"groupId": "OG001", "value": "1.61", "lowerLimit": "0.90", "upperLimit": "2.33"}]}]}]}, {"type": "SECONDARY", "title": "Night-time Wakenings", "description": "Average number of night-time wakenings in plant seed oil vs. placebo", "populationDescription": "one participant is missing some night-time wakening data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "average number of night-time wakenings", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "lowerLimit": "0.05", "upperLimit": "0.27"}, {"groupId": "OG001", "value": "0.13", "lowerLimit": "0.02", "upperLimit": "0.23"}]}]}]}, {"type": "SECONDARY", "title": "Urinary Leukotriene Levels", "description": "Urinary leukotriene levels in plant seed oil vs. placebo", "populationDescription": "one participant was missing some urinary leukotriene data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/ml", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)"}, {"id": "OG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.101", "lowerLimit": "0.085", "upperLimit": "0.117"}, {"groupId": "OG001", "value": "0.088", "lowerLimit": "0.072", "upperLimit": "0.105"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events data were collected for one year.", "description": "Adverse events data were collected for one year, from the time of first patient enrollment to the last date of adverse event resolution.", "eventGroups": [{"id": "EG000", "title": "Plant Seed Oil", "description": "Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of \\~ 1.7 g/day of GLA and 0.7 g/day of SDA)", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 13, "otherNumAtRisk": 28}, {"id": "EG001", "title": "Placebo", "description": "Placebo (11 g of corn oil/day)", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 14, "otherNumAtRisk": 28}, {"id": "EG002", "title": "Washout After Plant Seed Oil", "description": "Washout period between first (plant seed oil) and second (placebo) treatment assignments", "seriousNumAffected": 1, "seriousNumAtRisk": 14, "otherNumAffected": 6, "otherNumAtRisk": 14}, {"id": "EG003", "title": "Washout After Placebo", "description": "Washout period between first (placebo) and second (plant seed oil) treatment assignments", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 5, "otherNumAtRisk": 14}], "seriousEvents": [{"term": "Wheeze", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "subject experienced phlegm, cough, and wheeze during washout phase", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}], "otherEvents": [{"term": "Drop in Hemoglobin", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "drop in hematocrit", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "stomach ache", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "food poisoning", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "urticaria", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "allergies", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "candidiasis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "uterine fibroid", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Upper Respiratory Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "cough, chest tightness", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "worsening asthma symptoms", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "bruised rib", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Elliot Israel, MD", "organization": "Brigham and Women's Hospital", "email": "eisrael@partners.org", "phone": "617-732-2801"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Bronchial Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000079363", "term": "Borage oil"}], "ancestors": [{"id": "D000018501", "term": "Antirheumatic Agents"}], "browseLeaves": [{"id": "M254902", "name": "Borage oil", "asFound": "Metamucil", "relevance": "HIGH"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "T82", "name": "Borage", "asFound": "Anovulatory", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "HB", "name": "Herbal and Botanical"}]}}, "hasResults": true}